BridgeMD
New treatment option for Upper Tract Urothelial Cancer
Official title Single-Port RAS Using Da Vinci SP Surgical System for UTUC Patients
ClinicalTrials.gov ID: NCT06987552
What this study is testing
- What it's testing
- To evaluate patient-reported outcomes of radical nephroureterectomy using single-port robotic surgery
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 and older
You may be able to join if
- Age 20 years or more
- Histologically or cytologically diagnosed upper tract urothelial cancer
- Fitting indications of radical nephroureterectomy and ipsilateral bladder cuff resection, and deemed feasible for robotic surgery
- ASA physical status classification 1-2 and adequate organ function
- Patients willing and able to comply with study protocol requirements and follow-up
You likely can't join if
- Synchronous bladder cancer
- Distant metastasis of cancer
- BMI ≥30 or BMI \<18.5
- Unable to tolerate lateral decubitus or Trendelenburg position (relative contra-indication)
- Severe adhesion due to prior abdominopelvic surgery (relative contra-indication)
- Previous radiation treatment to the pelvic area
See the full eligibility criteria
- Age 20 years or more
- Histologically or cytologically diagnosed upper tract urothelial cancer
- Fitting indications of radical nephroureterectomy and ipsilateral bladder cuff resection, and deemed feasible for robotic surgery
- ASA physical status classification 1-2 and adequate organ function
- Patients willing and able to comply with study protocol requirements and follow-up
- With informed consent
- Synchronous bladder cancer
- Distant metastasis of cancer
- BMI ≥30 or BMI \<18.5
- Unable to tolerate lateral decubitus or Trendelenburg position (relative contra-indication)
- Severe adhesion due to prior abdominopelvic surgery (relative contra-indication)
- Previous radiation treatment to the pelvic area
- Active infectious disease
- Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic interventions, such as: severe heart disease (NYHA functional class III-IV) or severe lung disease (GOLD Group C-D)
- Cannot follow trial-required procedures
- Concomitant systemic or pelvic disease that increases the risk of surgery
- Long-term use of anti-coagulant(s)
- Patients with coagulopathy
- Emergency surgery
The study team makes the final eligibility decision.
Where it's taking place
- Taipei, Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Taipei, Taiwan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.